Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
Thu, 24.04.2025
Pfisterer Holding SE
CORPORATE NEWS
April 24, 2025NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS RELEASE.PFISTERER Holding SE plans In [ … ]
Thu, 24.04.2025
Evotec SE
Key scientific achievements expand the pipeline of high value molecular glue degraders for unmet medical needs
Performance-based and program-based payments of in total US$ 75 m to Evotec
Hamburg, Germany, 24 April 2025:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced furt [ … ]
Thu, 24.04.2025
Vossloh Aktiengesellschaft
Record order backlog at the end of Q1/2025 impressively underlines Vossloh's strong performance; positive outlook for 2025 confirmed
Orders received remained with €339.2 million on a high level, Book-to-bill ratio rises to 1.35
Order backlog of €926.4 million at a new all-time high, 15.2 percent up on the previous year
On-schedule start into fi [ … ]
Thu, 24.04.2025
Delivery Hero SE
Delivery Hero confirms full-year 2025 guidance after strong Q1 results
Q1 2025 Highlights
Group Gross Merchandise Value (GMV) of €12.4 billion, up 9%1 on a like-for-like basis year-over-year (YoY)
Total Segment Revenue growth of 22%1 YoY on a like-for-like basis to €3.5 billion
On track to deliver on FY 2025 guidance
Strong cash position and [ … ]
Thu, 24.04.2025
Heidelberg Pharma AG
Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2025
Cohort 7 of the clinical trial of HDP-101 in multiple myeloma safe and well tolerated
Cohort 8 expected to start soon
Clinical development of the second ADC program HDP-102 in patients with non-Hodgkin lymphoma (NHL) has started
Amendment of contract with [ … ]
Thu, 24.04.2025
Bühler Management AG
Ad hoc announcement pursuant to Art. 53 LR
Uzwil (Switzerland), April 24, 2025 – Bühler Group remains committed to its long-term orientation as a family business. Through proactive personnel and leadership planning, Bühler ensures continuity and stability for its employees, customers, and partners. The Board of Directors is therefore announcing the [ … ]
Thu, 24.04.2025
INFICON Holding AG
Corporate ContactMatthias TröndleChief Financial Officer+423 388 3510 matthias.troendle@inficon.com'Ad hoc announcement pursuant to Art. 53 LR'
Announcement of INFICON Holding AGBad Ragaz/Switzerland, April 24, 2025
• First quarter 2025 sales of USD 158.3 million 2.7% (organically: 4.7%) over prior-year period; positive order trend with a book- [ … ]
Thu, 24.04.2025
Belimo Holding AG
Strong business momentum in Q1, driven by adoption of data center technologies, prompts outlook upgrade.
In Q1, Belimo achieved net sales growth of 21.8% in local currencies and 23.6% in Swiss francs to CHF 275.8 million (Q1 2024: CHF 223.0 million). Performance across all regions surpassed projections, led by particularly strong results in the A [ … ]
Wed, 23.04.2025
STRATEC SE
STRATEC REPORTS PRELIMINARY BUSINESS RESULTS FOR 2024, PROVIDES GUIDANCE FOR 2025, AND POSTPONES 2024 ANNUAL REPORT
Birkenfeld, April 23, 2025
STRATEC SE, Birkenfeld, Germany, (Frankfurt: SBS; Prime Standard, SDAX) hereby announces that, following joint analysis with the external auditor appointed for the first time for the 2024 financial year, i [ … ]
Wed, 23.04.2025
H2APEX Group SCA
H2APEX receives shareholder loan and plans capital increase for further expansion of its hydrogen production capacities
Loan agreement concluded on attractive terms with shareholder Active Ownership with a volume of EUR 20 million
Additional comfort letter from an investor of the Atlan Group for a further EUR 15 million
Financing from the two ma [ … ]